GenSight Biologics S.A.

• The EIB credit facility will enable GenSight Biologics to support the development of its pipeline and in particular the preparation of the marketing of LUMEVOQ® in Europe
• The €35.0m credit facility consists of three tranches available within 24 months from signing and each having a 5 year maturity
• The credit facility is part of the EIB’s strategy to support biotech companies developing a high-level of expertise in various therapeutic areas with significant unmet medical needs
• Following the Joint Bookrunner Role in GenSight’s March 2021 €30 million capital increase, Kempen & Co is proud to have assisted the company as a repeat client
• In difficult market circumstances, Kempen & Co has been able to successfully assist its client with an innovative financing solution. This transaction underpins our ambition to serve our clients with a wide variety of tailormade financing structures

GenSight Biologics S.A. is a biopharma company focused on developing and commercialising innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. Using its gene therapy approach, GenSight Biologics' drug candidates are intended to provide patients with lasting functional recovery after a single intravitreal injection into each eye. Developed for the treatment of Leber’s Hereditary Optic Neuropathy (LHON), GenSight Biologics' lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), is under review for registration in Europe and in Phase III prior to the filing of a Biologics License Application (BLA) in the United States. 

In the last twelve months, Kempen & Co has successfully completed a number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

• Joint Global Coordinator and Joint Bookrunner in Xbrane’s SEK 170 million Capital Increase
• Co-Lead Manager in Zealand Pharma’s DKK 786 million Capital Increase
• Sole Financial Adviser in Mendus’ up to SEK 250 million of financing commitments
• Sole Financial Adviser in the sale of Sanquin Reagents by Sanquin Health Solutions to Gilde Healthcare
• Joint Global Coordinator in BioInvent’s SEK 299 million directed share issue
• Sole Global Coordinator Abliva’s SEK 200 million financing consisting of a SEK 150m PIPE and a SEK 50m Fully Guaranteed Rights Issue 
• Joint Global Coordinator & Joint Bookrunner in SynAct Pharma’s SEK 150 million Fully Guaranteed Rights Issue 
• Co-Manager in the USD 700 million Capital Increase by argenx
• Sole Block Placing Agent in the placement of 1.4m Molecular Partners shares
• Joint Bookrunner in the USD 127 million Nasdaq IPO of Forbion European Acquisition Corp
• Co-Lead Manager in the USD 115 million Nasdaq IPO by IO Biotech 
• Lead manager in the USD 127 million Global Offering of Merus